Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOZANTINIB S-MALATE Cause Erythema multiforme? 28 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Erythema multiforme have been filed in association with CABOZANTINIB S-MALATE (CABOMETYX). This represents 0.1% of all adverse event reports for CABOZANTINIB S-MALATE.

28
Reports of Erythema multiforme with CABOZANTINIB S-MALATE
0.1%
of all CABOZANTINIB S-MALATE reports
0
Deaths
14
Hospitalizations

How Dangerous Is Erythema multiforme From CABOZANTINIB S-MALATE?

Of the 28 reports, 14 (50.0%) required hospitalization.

Is Erythema multiforme Listed in the Official Label?

Yes, Erythema multiforme is listed as a known adverse reaction in the official FDA drug label for CABOZANTINIB S-MALATE.

What Other Side Effects Does CABOZANTINIB S-MALATE Cause?

Diarrhoea (8,282) Fatigue (6,819) Off label use (5,245) Nausea (4,341) Decreased appetite (4,076) Blood pressure increased (2,939) Malignant neoplasm progression (2,718) Palmar-plantar erythrodysaesthesia syndrome (2,706) Weight decreased (2,657) Stomatitis (2,560)

What Other Drugs Cause Erythema multiforme?

IBUPROFEN (226) NIVOLUMAB (221) PEMBROLIZUMAB (212) LAMOTRIGINE (210) ACETAMINOPHEN (172) PACLITAXEL (166) AMOXICILLIN (164) ALLOPURINOL (147) CARBOPLATIN (146) CLARITHROMYCIN (131)

Which CABOZANTINIB S-MALATE Alternatives Have Lower Erythema multiforme Risk?

CABOZANTINIB S-MALATE vs CAFFEINE CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL-MKNL CABOZANTINIB S-MALATE vs CALCIFEDIOL CABOZANTINIB S-MALATE vs CALCIPOTRIENE

Related Pages

CABOZANTINIB S-MALATE Full Profile All Erythema multiforme Reports All Drugs Causing Erythema multiforme CABOZANTINIB S-MALATE Demographics